P/E at 19.05 vs Industry's 33.83: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amid Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd at 19.05 stands in stark contrast to the industry average of 33.83, indicating the stock is trading at a 44% discount relative to its sector peers. This valuation gap is particularly striking given the Pharmaceuticals & Biotechnology sector’s reputation for commanding premium multiples due to growth prospects and defensive qualities. The discount may reflect concerns over recent performance or broader market sentiment, but it also suggests the stock is priced with a margin of safety compared to its industry cohort. Previously rated Buy, what is Dr Reddys Laboratories Ltd’s current rating? The valuation differential is a key factor in this reassessment.

Performance Across Timeframes: Mixed Signals

Examining returns over multiple periods reveals a nuanced picture. Over the past year, Dr Reddys Laboratories Ltd has delivered a 10.39% gain, outperforming the Sensex’s 3.95% decline by a wide margin. This outperformance underscores resilience amid broader market weakness. However, the shorter-term trend is less clear-cut. The stock’s three-month return of 3.16% is positive but modest, especially when compared to the Sensex’s 7.33% loss, indicating some recent relative strength. Conversely, the one-week performance shows a 3.74% decline, underperforming the Sensex’s flat 0.05% movement. This divergence between medium and short-term returns suggests a recent pullback after a period of strength — is this a temporary correction or a sign of deeper weakness? The one-month return of 5.19% versus the Sensex’s 4.52% gain further complicates the momentum narrative, highlighting the stock’s oscillating trend.

Moving Average Configuration: Technical Insights

The technical setup of Dr Reddys Laboratories Ltd offers additional context. The stock currently trades above its 20-day, 50-day, 100-day, and 200-day moving averages, signalling underlying medium to long-term strength. However, it remains below its 5-day moving average, indicating some short-term hesitation or consolidation. This configuration often points to a recent pause or minor pullback within a broader uptrend. The stock’s gain today of 0.74%, outperforming the sector by 1.01%, follows a four-day losing streak, suggesting a potential trend reversal or relief rally. The 5% surge partially reverses a 6.45% monthly decline — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The moving average configuration provides the clearest answer.

Sector Performance Context

The Pharmaceuticals & Biotechnology sector has seen uniformly positive results recently, with all six stocks that declared results posting gains. This broad-based strength contrasts with the more mixed performance of Dr Reddys Laboratories Ltd over the short term, highlighting the stock’s idiosyncratic challenges or opportunities. The sector’s robust performance underlines the defensive and growth attributes investors continue to favour, yet should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider? The current rating provides the answer.

Rating Reassessment and Market Capitalisation

Previously rated Buy by MarketsMOJO, Dr Reddys Laboratories Ltd had its rating updated on 04 May 2026. The stock’s large-cap status, with a market capitalisation of ₹1,06,081 crore, places it among the sector’s heavyweight constituents. The reassessment likely reflects the interplay of valuation discount, mixed short-term momentum, and technical signals. The Mojo Score of 64.0 and previous Hold grade suggest a cautious stance, balancing the stock’s relative strength against recent volatility and sector dynamics.

Comparative Returns Over Longer Horizons

Looking beyond the immediate term, Dr Reddys Laboratories Ltd has delivered a 29.68% return over three years, slightly outperforming the Sensex’s 26.86%. However, over five years, the stock’s 23.93% return trails the Sensex’s 58.23%, and over ten years, the stock’s 123.21% gain is well behind the Sensex’s 207.01%. These figures suggest that while the company has shown resilience and growth, it has not consistently matched the broader market’s long-term performance. This mixed track record may contribute to the current valuation discount and rating reassessment.

Short-Term Momentum and Daily Performance

On the daily front, Dr Reddys Laboratories Ltd outperformed the Sensex with a 0.74% gain compared to the benchmark’s 0.57%. This positive day performance follows a four-day losing streak, indicating a potential short-term reversal. The stock opened at ₹1292.95 and traded steadily at this level, reflecting some stability after recent volatility. The interplay between daily gains and short-term moving averages below the 5-day average suggests investors are watching closely for confirmation of a sustained recovery or further consolidation.

Conclusion: What the Data Collectively Shows

The data on Dr Reddys Laboratories Ltd paints a complex picture. The stock’s valuation discount relative to its sector peers is significant, suggesting either undervaluation or concerns about near-term prospects. Performance across timeframes is mixed, with strong one-year returns but recent short-term weakness. The moving average configuration indicates a potential pause within a longer-term uptrend, while sector-wide positive results contrast with the stock’s more cautious momentum. The recent rating reassessment from Buy to Hold by MarketsMOJO reflects these nuances. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider? The current rating provides the answer.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →